SLC35D3: A Protein Involved in Neurodegeneration, Pain Perception and Drug Targeting

Target Name: SLC35D3

NCBI ID: G340146

SLC35D3

SLC35D3: A Protein Involved in Neurodegeneration, Pain Perception and Drug Targeting

SLC35D3, also known as Frc or Fringe-like 1, is a protein that is expressed in various tissues throughout the body. It is a member of the solute carrier family 35 (SLC35) and is characterized by its ability to transport a wide range of molecules, including small molecules, ions, and proteins across cell membranes. SLC35D3 has been identified as a potential drug target and has been shown to play a role in a variety of biological processes, including cellular signaling, neurodegeneration, and pain perception.

SLC35D3 is a transmembrane protein that is expressed in a variety of tissues, including brain, heart, liver, and kidney. It is primarily localized to the endoplasmic reticulum (ER) and is thought to play a role in regulating the delivery of proteins to the plasma membrane (PM) through the endosomal system. This system is responsible for the transport of proteins from the ER to the PM, where they can be involved in a variety of cellular processes.

One of the unique features of SLC35D3 is its ability to transport a wide range of molecules across cell membranes. This is due to the presence of multiple transmembranespanning regions (TMRs) on the protein, which allow it to interact with a variety of different molecules. SLC35D3 has been shown to transport a variety of different molecules, including small molecules, ions, and proteins. For example, studies have shown that SLC35D3 can transport neurotransmitters, such as dopamine and GABA, across brain cell membranes.

In addition to its role in transport, SLC35D3 is also involved in the regulation of intracellular signaling processes. For example, studies have shown that SLC35D3 can interact with the protein p53 and can modulate its activity. This suggests that SLC35D3 may play a role in the regulation of p53-mediated signaling pathways, which are important for a variety of cellular processes, including DNA repair, cell growth, and apoptosis.

SLC35D3 has also been shown to be involved in the regulation of neurodegeneration. For example, studies have shown that SLC35D3 is expressed in the brains of mice and that its expression is modulated by conditions that are associated with neurodegeneration, such as stroke and Alzheimer's disease. Additionally, SLC35D3 has been shown to interact with the protein Tau and can modulate its activity, which suggests that it may play a role in the regulation of neurodegeneration.

In addition to its role in neurodegeneration, SLC35D3 has also been shown to be involved in the regulation of pain perception. For example, studies have shown that SLC35D3 is expressed in the spinal cord and that its expression is modulated by conditions that are associated with pain, such as heat or pressure. Additionally, SLC35D3 has been shown to interact with the protein TrkA, which is involved in the regulation of pain signaling pathways.

SLC35D3 has also been shown to have potential therapeutic applications. For example, studies have shown that SLC35D3 can be targeted to the brain and that its expression is modulated by conditions that are associated with neurodegeneration, such as stroke and Alzheimer's disease. Additionally, SLC35D3 has been shown to interact with the protein S100, which is involved in the regulation of neural stem cell proliferation and differentiation. This suggests that SLC35D3 may be a potential therapeutic target for

Protein Name: Solute Carrier Family 35 Member D3

Functions: May play a role in hemostasis as a regulator of the biosynthesis of platelet-dense granules

The "SLC35D3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35D3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets